COPENHAGEN, Aug. 27 (Xinhua) -- Danish pharmaceutical company Novo Nordisk on Wednesday announced the acquisition of a biologics manufacturing facility in West Lebanon, New Hampshire, the United States, from Olympus Biotech.
Novo Nordisk said it will use the facility for production of active pharmaceutical ingredients primarily for its portfolio of biopharmaceuticals.
Some of the plant's former employees have been offered jobs, which initially will focus on planning of the future plant setup, it added.
However, the terms of the acquisition are not disclosed.
The plant was established in 1989 and acquired by Olympus Biotech in 2011. It had been used primarily for mammalian cell manufacturing until production was phased out earlier this year.
Olympus Biotech is a wholly owned subsidiary of Olympus Corporation and was established in late 2010 to build on Olympus' experiences in the medical technology industry.
Headquartered in Denmark, Novo Nordisk is a healthcare company boasting more than 90 years of innovation in diabetes care. It employs approximately 40,700 employees in 75 countries and regions, and markets its products in more than 180 countries and regions.